This work provides evidence for a “butyrate-IDO1-ILA” axis as a potential target of TCM in NASH, highlighting the modulation of gut microbiota-host interactions as a promising therapeutic strategy. This evidence concerns the gene IDO1 and metabolic dysfunction-associated steatohepatitis.